Ambrx Biopharma Inc. Stock News

Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed Two patients in Cohort 9 exper

Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology fo

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging anti-tumor activity with cohorts 6 through 8. In order to see if ARX517 can be improved upon for

Newly published data from the Phase 1 portion of the on-goingPhase 1 / 2 APEX-01 trial provide the following key points: Multiple efficacy endpoints demonstrate consistent and promising anti-cancer ac

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6 (2

The company, formerly based in the Cayman Islands, is moving to Delaware. It is expected to announce trial data next week regarding two of its lead therapies.

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx

Here is how Ambrx Biopharma Inc. Sponsored ADR (AMAM) and Sientra (SIEN) have performed compared to their sector so far this year.

Presentations represent the first time clinical data regarding ARX517 will be presented at a medical meeting Presentations represent the first time clinical data regarding ARX517 will be presented at

SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (or the “Company”) (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambr

Ambrx Biopharma's stock value has surged due to positive preliminary data from cancer-targeting clinical trials of ARX788 and ARX517. With cash reserves increasing to $149.6 million in Q1 2023, Ambrx

Ambrx's lead therapies target breast cancer and prostate cancer, two of the most common forms of cancer. The company has enough cash, it said, to fund operations for another year.

Ambrx Biopharma Inc. is up 40x since February after posting positive clinical data. However, that sort of rally makes a stock unstable.

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O'Connor, Chief Executive Officer and President of Ambrx, will present a corpo

Three posters will be presented at AACR and include data from preclinical studies of ARX517 and ARX305 and Trial in Progress Poster on APEX-01 Three posters will be presented at AACR and include data